



Member/Affiliate Name: _____
Name of Core: _____
Reporting Period: _____

Each CHIPTS member and affiliate should complete this form and submit it to your core contact person by the specified due date.

- Uyen Kao for Administrative Core, ukao@mednet.ucla.edu
- Dallas Swendeman for Development Core, DSwendeman@mednet.ucla.edu
- Jae Lee for Methods Core, SJLee@mednet.ucla.edu
- Dami Jolayemi for Combination Prevention Core, OJolayemi@mednet.ucla.edu
- Diane Tan for Policy Impact Core, diane.tan@ucla.edu

The **BLUE text** is provided as examples only. This information will be used to compile and write our annual Center progress report due to NIMH.

1. **Grants Submitted/Awarded:** Please include title, funder, when it was submitted, 1-2 sentence description of the study, collaborators if applicable, and status of application (e.g. awarded, pending review, not funded). Cross-core collaboration are highly encouraged, so please make sure to highlight other core members that are involved in our grants.
 - *Dr. Reback (PI) of the Combination Prevention Core and Dr. Holloway (Co-I) of Policy Core submitted a NIDA R21 grant application entitled "Social Networks and Technology Use of Transgender Women with/at High risk for HIV." The study seeks to conduct formative research to examine how the egocentric structure and composition of transgender women's social networks and social network sites/technology use affect their engagement in HIV risk/protective behaviors. (funded on mm/dd/yy)*
2. **Proposal development consultation:** Provide title or topic of proposal, for whom did you provide the consult, what was the consult (e.g. provide feedback on specific aims section), when was the consult done, what type of proposal (e.g. pilot grant, R01, etc), and where was the proposal submitted (e.g. NIDA, NIMH, CHRP, etc)
 - *Drs. Shoptaw, Murphy, and Landovitz provided consultation and written feedback to Dr. Ron Brooks on his R21 grant application "PrEP Stigma a Potential Barrier to Diffusion and Retention to PrEP among Latino and Black MSM" which was submitted to NIMH in September 2014. (Status of funding).*

3. **Other scientific consultation:** Please provide for whom did you provide the consult, what was the consult, when was it done. This includes any grant reviews you have conducted. Just send any activities that you have done, even if you are unsure if it counts as a consultation. We will assess if the activity counts as a consult later.
 - *Dr. Shoptaw provided consultation to Dr. Steffanie Strathdee of UCSD, on formulating a post-VG trial design for IDUs to study the effectiveness of various intervention combinations to reduce HIV incidence, in March 2014.*

4. **Journal Reviews:** Please provide when the review was done, title of manuscript, and name of journal
 - *Archives of Sexual Behaviors, "Pilot Randomized Controlled Trial of an Integrative Intervention with Methamphetamine-using Men Who Have Sex with Men," July 2014.*

4. **Trainings/event conducted:** Please include date of event, title of talk, location, and for whom.
 - *Drs. Shoptaw and Gorbach gave a presentation on "Immune Activation Measures in GALT in ART Naive Methamphetamine-Using HIV Positive MSM" for the Society on NeuroImmune Pharmacology 20th Annual Scientific Conference on March 28, 2014 in New Orleans.*

5. **Mentorship.** Include name of mentee, mentored on what, period of mentorship, etc. This applies also to ongoing mentorship. Please include any accomplishments from mentees that have resulted from your mentorship (e.g. publications, grants, honors, awards, faculty positions achieved by your mentees or fellows).
 - *Dr. Shoptaw provides ongoing mentorship to Dr. Keith Hermanstynne, who is developing a concept sheet for HPTN 061 data to do a social network analysis on drug-using patterns in the data set.*

5. **Network memberships** (e.g. advisory boards, board of directors, etc) include the time period in which you are active on these networks

6. **Other noteworthy accomplishments.** Please include any other accomplishments that you would like to report. These can include any special honors or recognition that you have received, special collaborations and partnerships that you have established, any press/media coverage, or any citations or documentations of your work influencing any public or community change.

7. **Publications (accepted, in press, and submitted):** PLEASE include only publications which resulted from P30MH058107, which is the CHIPTS grant number. Also please make sure that they are compliant with the NIH Public Access Policy and recorded in your MyNCBI/MyBibliography. Please contact Izzy Chu at IChu@mednet.ucla.edu if you need help on this.
8. **Technologies or techniques.** Identify technologies or techniques that have resulted from the research activities. Describe the technologies or techniques and how they are being shared. This may not be applicable to some of you, but “technologies or techniques” are broadly defined here. This could include a unique medication/clinical protocol, mobile application, technique for analyzing data, etc.
9. **Foreign Component:** Please provide the organization name, country, and description of each foreign component. Foreign component is defined as any “significant scientific activity” (e.g. involving human subjects, collection of data, co-authorship on papers, resource sharing, use of facilities, etc.) done outside of the U.S.

Organization name	Country	Description of activity/relationship (1-3 sentences)
<i>University of XYZ Jane Smith, PhD, MD</i>	<i>Cape Town, South Africa</i>	<i>One of three study sites of a RCT of an HIV disclosure intervention study. The study aims to Study involves recruitment and enrollment of HIV positive mothers into a 12 week intervention and assessments at baseline, 3 months, and 6 months. etc.</i>
<i>HIV Center of ABC Joe Smith, PhD</i>	<i>Peru</i>	<i>Working with Dr. Scientist on a longitudinal analysis looking at variables A, B, and C among high risk HIV positive MSM. The collaboration have resulted in the a manuscript published in AIDS and Behavior.</i>
